Skip to main content
NMD-VCell Research OSDisease state → cell state → target → experiment
SearchLaunch Workspace
View: Plain
Release 2026.08DMD context observedDMD candidate-conditioned prediction not yet eligible
View scientific status
Evidence freeze: 3 August 2026Resource: v1.2.0-measured-dmd-evidenceSchema: 1.1Open release status
Explore NMD-VCell

Gene evidence summary

RNASEH2C

Current recommendation: Review safety and biological context.

What we know

RNASEH2C was experimentally perturbed in HepG2 cells.

What remains uncertain

The available DMD summaries are contextual evidence, not perturbation truth. A matched perturbation in a DMD-relevant muscle model is the truth needed to calibrate a future DMD-response model.

What should happen next

Review safety and biological context. Use independent reagents and biological replication, and predeclare one functional endpoint.

Current value: this record identifies the most informative next experiment and the result needed for model calibration. It does not yet establish a therapeutic or clinical conclusion.

Design this experimentReview research evidenceCompare evidenceOpen core data

Evidence journey

Where RNASEH2C stands—and what creates the next evidence

Read left to right from released knowledge to translation. The highlighted next step is a research decision, not a target score.

Inspect datasets and methods →
01 · Database supportVersioned gene recordStable identity, provenance and downloadable evidence are available.
02 · Disease contextDMD context assembledSource-specific DMD signals are retained separately for interpretation.
03 · Model evidenceCalibration truth neededThe current evidence defines what a future DMD-response model must learn and test.
04 · Experimental perturbationObserved outside DMD muscleThe HepG2 response is useful for context transfer, not yet DMD truth.
05 · Functional phenotypeNext decision experimentReview safety and biological context
06 · Clinical evidenceFuture translation layerClinical interpretation follows reproducible disease-matched functional evidence.

Data behind this summary

Exact values currently available for RNASEH2C

These values come from different biological contexts and are displayed separately. They are not combined into one target score.

Open all dataset rows →
HepG2 perturbation coverage132 cellsCells in the frozen aggregate; not biological replicates.
Skeletal-muscle expression9.52581 TPMGTEx v8 tissue-expression context; not perturbation evidence.
DMD source effects4/4 directions agree4 source-specific effects retained without pooling.
Human-myoblast fusion screenLFC 0.18037 · FDR 0.685016Assessed no-hit at FDR < 0.1; not evidence of no muscle function.

What this candidate is for

Does RNASEH2C have a dependency, toxicity or context-specific safety profile that blocks escalation?

A candidate record authorizes a bounded question and next experiment. It does not authorize a therapeutic or clinical claim.

Practical useDecide whether a usable perturbation window exists before testing disease relevance.
Decision available nowSafety and dependency context require review before a larger perturbation experiment.
What blocks itSafety and dependency context blocks escalation
Minimum next actionRun a context-matched dose/time and viability review for RNASEH2C with engagement and stop rules declared in advance.
How would the result change the decision?

SupportiveAdvance to a functional muscle assay only if a reproducible window passes engagement and viability gates.

NullStop escalation and retain the negative feasibility evidence if no acceptable window remains.

Inconclusive / QC failureClassify a donor-, dose- or reagent-specific window as context dependent and redesign first.

Open Study CardPlan the experimentCompare decision gaps

Plain view presents the current story. Open Research for evidence details or Audit for machine fields and provenance.